Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.77
-6.5%
$6.34
$4.77
▼
$25.95
$234.39M1.19679,958 shs640,566 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$0.50
-5.6%
$0.77
$0.50
▼
$2.38
$224.97M0.872.65 million shs3.45 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.75
-1.6%
$4.40
$3.57
▼
$9.94
$230.39M0.741.31 million shs948,919 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$1.50
-1.3%
$1.40
$0.62
▼
$8.01
$72.04M-2.3345,727 shs22,561 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-2.30%-11.76%+5.37%-52.56%-38.63%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-3.03%-10.30%-25.47%-48.90%-49.39%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%-6.62%-5.46%-31.60%-13.41%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
+6.29%-1.30%+8.57%-17.84%-30.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.77
-6.5%
$6.34
$4.77
▼
$25.95
$234.39M1.19679,958 shs640,566 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$0.50
-5.6%
$0.77
$0.50
▼
$2.38
$224.97M0.872.65 million shs3.45 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.75
-1.6%
$4.40
$3.57
▼
$9.94
$230.39M0.741.31 million shs948,919 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$1.50
-1.3%
$1.40
$0.62
▼
$8.01
$72.04M-2.3345,727 shs22,561 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-2.30%-11.76%+5.37%-52.56%-38.63%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-3.03%-10.30%-25.47%-48.90%-49.39%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%-6.62%-5.46%-31.60%-13.41%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
+6.29%-1.30%+8.57%-17.84%-30.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
2.63
Moderate Buy$29.00507.97% Upside
Canopy Growth Corporation stock logo
CGC
Canopy Growth
2.25
HoldN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.56
Moderate Buy$13.50260.00% Upside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ZYBT, CGC, BIOA, and VNDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Lower Price TargetBuy$21.00 ➝ $20.00
11/9/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Reiterated RatingBuy
11/4/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
UpgradeStrong Sell ➝ Hold
11/2/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingBuy
10/26/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeSell (E+) ➝ Sell (D-)
10/16/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-) ➝ Sell (E+)
10/16/2026
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
Reiterated RatingSell (D)
10/15/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingSell (D-)
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Initiated CoverageNeutral$8.00
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeHold
10/8/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$8.99M24.39N/AN/A$7.54 per share0.63
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$251.01M0.85N/AN/A$1.10 per share0.46
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$216.10M1.05N/AN/A$3.31 per share1.13
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$16.64M4.27N/AN/A$0.93 per share1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$80.61M-$2.55N/AN/AN/A-1,253.60%-31.42%-29.59%N/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$190.29M-$0.51N/AN/AN/A-73.03%-28.21%-17.97%N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$220.47M-$4.62N/AN/AN/A-119.87%-62.70%-37.53%N/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-$9.98MN/AN/AN/AN/AN/AN/AN/AN/A

Latest ZYBT, CGC, BIOA, and VNDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q2 2026
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A-$0.03N/A-$0.03N/A$3.75 million
11/6/2026Q2 2027
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.02-$0.07-$0.05-$0.07$57.72 million$57.28 million
11/5/2026Q3 2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$0.68-$0.73-$0.05-$0.73N/A$0.30 million
10/28/2026Q3 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.6820-$0.37+$0.3120-$0.37$69.20 million$69.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
15.51
15.51
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.31
2.82
2.20
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.01
1.54
1.53
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A

Insider Ownership

CompanyInsider Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
17.55%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.35%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.70%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
6245.96 million37.89 millionOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1,128423.35 million421.87 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
53360.47 million54.00 millionOptionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
26947.39 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology Holding Ltd (ZYBT)
Zhengye Biotechnology Holding Ltd ZYBT

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs stock logo

BioAge Labs NASDAQ:BIOA

$4.77 -0.33 (-6.47%)
Closing price 04:00 PM Eastern
Extended Trading
$4.83 +0.06 (+1.26%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$0.50 -0.03 (-5.63%)
Closing price 04:00 PM Eastern
Extended Trading
$0.51 +0.00 (+0.90%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$3.75 -0.06 (-1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$3.85 +0.10 (+2.64%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$1.50 -0.02 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 -0.02 (-1.60%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.